Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with
and without PD-1 blockade and with and without imiquimod. A device called the Echopulse will
be used for the FUSA therapy. Patients will be assigned to 1 of 2 cohorts depending on their
disease and treatment status. In Cohort 1, patients will receive FUSA therapy while receiving
PD-1 blockade therapy as part of standard clinical care treatment. In Cohort 2, patients who
discontinue or are ineligible for PD-1 blockade therapy will undergo FUSA without concurrent
systemic therapy, with the goal of utilizing the FUSA to boost the innate immune response.
The optional secondary regimen will combine FUSA (+/- PD-1 blockade) with imiquimod, which is
a topical TLR7 agonist.